张健致诚书院院长、教授、博士生导师


zhangjian@sustech.edu.cn
生物楼503
进入个人主页返回到师资列表
个人简介张健，南方科技大学医学院教授，博士生导师，致诚书院院长， “百千****才工程”国家级人选，国务院特贴专家，深圳市引进国家级领军人才，中国抗癌协会肿瘤转移专业委员会常委兼青委会主任委员，中国医药生物技术学会转化医学分会副主任委员，中国细胞生物学会医学细胞生物学分会常委，深圳市生物医药促进会副会长，中国抗癌联盟深圳市联盟副主席，曾创建“长寿与老年相关疾病” 教育部重点实验室任首任主任，目前担任广东省细胞微环境与疾病研究重点实验室学术委员会和深圳市细胞微环境重点实验室学术委员会委员。2015-2017年担任《Medical Oncology》副主编。SCI 发表文章总数100余篇。 博士毕业于美国密西根大学医学院，2004 年起任美国国防部（DOD）医学课题评审委员，从2009 年起任我国教育部****和自然科学基金终审评审专家。2012 年被选为“全国优秀科技工作者”， 2013 年入选“国家百千****才工程”和“国家有突出贡献中青年专家”。2016年获批“深圳市引进国家级杰出人才”。主要研究方向：衰老基础与干预；肿瘤微环境与转移。


研究领域肿瘤转化医学研究
肿瘤耐药、复发与转移
衰老与肿瘤



教育背景1981-1986: 学士，天津医科大学临床医学系
1997-1998: 硕士，Old Dominion University & East Virginia Medical School 免疫学专业
1998-2001: 博士，University of Michigan 病理学专业



工作经历1986.8-1995.1 天津市第三医院/天津市老年医学研究所，内科住院医师、主治医师
1995.1-1996.8 美国威斯康星-麦迪逊大学老年医学研究所 世界卫生组织奖学金访问****
1996.8-1998.8 东弗吉尼亚医学院老年医学研究中心Visiting Research Scientist
1998.8-2004.6 美国密歇根大学医学院博士在学/研究员
2004.7-2010.12 美国匹兹堡大学和密歇根大学医学院助理教授 (Tenure track)
2011.1-2016. 7 长寿与老年相关疾病省部共建教育部重点实验室/广西医科大学转化医学院就中心主任/教授
2016.3- 美国匹兹堡大学医学院兼职教授
2016.7- 南方科技大学医学院教授



获奖情况及荣誉2019-深圳市生物医药促进会副会长
2018-中国肿瘤防治联盟深圳市联盟副主席
2014-获得国务院政府特殊津贴专家
2013-入选国家百千****才工程国家级人选并获“有突出贡献的中青年专家”荣誉称号
2013-美国基础泌尿研究学会(SBUR)颁发的International lecturer证书
2012-全国优秀科技工作者
2011-广西自治区八桂****、广西自治区政府参事
2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR
2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR
2003-Scholar-in-Training Award, AACR
2003- Plenary Poster Award of 25th Annual Meeting of American Society for Bone and Mineral Research
2002-Alice L. Jee Memorial Young Investigator Award
2000-Plenary Poster Award of 22nd Annual Meeting of American Society for Bone and Mineral Research
1994- Fellowship Award, World Health Organization (WHO)



杂志编委会成员Journals Ad hoc reviewer（受邀审稿人）
Journal of Gerontology; Biological Sciences; Bone; Cancer Research; The Prostate; Journal of Clinical Investigation; Clinical Cancer Research; Neoplasia; Molecular Cancer Research; Journal Bone Mineral Research; International Journal of Cancer; British Journal of Cancer; Molecular Cancer Therapeutics; Peptides; Journal of Cellular and Molecular Medicine; Cancer Immunology Therapeutics; Cancer Metastasis Reviews; Carcinogenesis; Oncotarget

Associate Editor (副主编)
Medical Oncology; Chinese Journal of Cancer

Editorial board member （编委）
The Open Prostate Cancer Journal; Chinese Journal of Lung Cancer; Thoracic Cancer



近年代表文章Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.J Clin Invest.107:1235-1244, 2001.
Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity.Antioxidant & Redox Signaling. 3:493-504, 2001.
Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice.J Bone Miner Res17:1256-1263, 2002.
Zhang J, J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone.Cancer Res.63:7883-90, 2003
Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo.Prostate.59:360-9, 2004
Zhang J, Dai J, Lu Y, Yao Z, O’Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging.Experimental Gerontology.39:239-247, 2004
Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z andZhang J*.Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.Prostate.66:1311-8, 2006
Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD,Zhang J*.Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption.Cancer Res,67:3646-53, 2007
Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, andZhang J*. CCR2 expression correlates with prostate cancer progression.J Cell Biochem.101:676-685, 2007
Lu Y, Yao Z, andZhang J*.Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment.Chin J of Biochem and Molecul Biol, 23(3):167-171, 2007
Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, andZhang J*.PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.Int J of Cancer.121:724-733, 2007
Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y,Zhang J*.Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation.Mol Cancer Therapeutics,7(10):3203-11, 2008
Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, andZhang J*.CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.Mol Cancer Res,6(4): 546-54, 2008
Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, andZhang J*.Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.Clin Exp Metastasis,26(2):161-9, 2009
Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, andZhang J*.MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo.Neoplasia, 11(3):228-236, 2009
Zhang J,Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.Cytokine Growth Factor Rev.21(1):41-8, 2010
Zhang J,Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth.J Natl Cancer Inst.102(8):522-8, 2010
Zhang J*,Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model.Neoplasia2011
Zhang J,Patel L, Pienta KJ.Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic.Progress in Molecular Biolology: Translational Sciences.2010;95:31-53.
Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET,Zhang J*,Deng J*，Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model.Plos One. 9(6):e100394, 2014
Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q,Zhang J*. Targeting Notch Signaling Pathway in Cancer Therapeutics.Thoracic Cancer, 2014, 5; 473-86
Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , andZhang J*. Translational progress on tumor biomarkers.Thoracic Cancer.27 JUL 2015, DOI: 10.1111/1759-7714.12294
YuZhu,ChunlinZou,ZheZhang,ChaonanQian,XinYang,JunlinShi,YuduiXia,Zhang J*,YiLu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression.TumorBiology, 2015, 36(11):8811-8.
ShaHe,YiLu,XiaLiu,XinHuang,EvanKeller, Chao-NanQian*,Zhang J*; Wnt3a:functionandimplicationincancer.ChineseJournalofCancer, 2015, 34(3):50.
Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*,ZhangJ*, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway.Oncotarget,7(10):11487-99, 2016.
Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*,Zhang J*. Exosome-derived microRNAs contribute to prostate cancer chemoresistance.International Journal of Oncology, 2016, 49:838-846.
Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller,Zhang J*, Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27.Oncology Reports, 2016, 36:559-566.
Yang Liu, Yi Chai,Zhang J*, and Junwei Tang*. A function variant at miR-501 alters susceptibility thepatocellular carcinoma in a Chinese han population.Cell Physiol Biochem,38(6):2500-8, 2016.
Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller,Zhang J, Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker.Oncotarget, 2016, Oct 18;7(42):68140-68150.
Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian,Jian Zhang*and Lu Y*. Metformin targets multiple signaling pathways in cancer.Chinese Journal of Cancer, 2017; 36(1):17.
GuoH,LuoH,YuanH,XiaY,ShuP,HuangX,LuY,LiuX,KellerET,SunD*,DengJ*, andZhangJ*. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling.Sci Rep. 2017; 7: 41656.
Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* andJian Zhang*. Down-regulation ofE-cadherin enhances prostate cancer chemoresistance viaNotch signaling.Chinese Journal of Cancer, 2017; 36:35
Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu,Jian Zhang,Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.Oncology Reports.2017
Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller,Jian Zhang, Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer.Chinese Journal of Cancer, 2017; 36:29